All the news Showing 10 of 46 articles from: Previous non-responders & relapsersGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Triple combination cures most hepatitis C patients with prior DAA treatment failure Liz Highleyman / 02 May 2017 Almost all people with genotype 1 hepatitis C who were previously unsuccessfully treated with a course of interferon-free direct-acting antiviral therapy achieved sustained response when retreated with a three-drug combination ... Investigational combination ABT-493 and ABT-530 works well in patients who did not achieve SVR12 with previous DAA therapy Michael Carter / 26 April 2016 An experimental combination of direct acting antivirals (DAAs) is effective and safe in HCV-genotype-1-infected patients who did not respond to previous DAA therapy, according to research presented to the recent International Liver Congress ... Merck HCV combination effective after failure of first generation of direct-acting antivirals Keith Alcorn / 24 April 2015 A 12-week course of treatment with two direct-acting antivirals in development by Merck plus ribavirin cured 95% of people with hepatitis C who had experienced failure of a previous treatment combination containing a ... Sofosbuvir/ledipasvir cures most previously treated hepatitis C patients with cirrhosis Liz Highleyman / 07 January 2015 Difficult-to-treat hepatitis C patients with liver cirrhosis who were not cured with a prior course of first-generation HCV protease inhibitors had a sustained response rate of 96-97% when re-treated with sofosbuvir/ledipasvir with ribavirin ... Regulus Therapeutics demonstrates human proof-of-concept with microRNA therapeutic for HCV News Medical Net / 22 October 2014 Bristol-Myers gets the approval Gilead didn't want: Daklinza + Sovaldi for hep C Fierce PharmaMarketing / 11 September 2014 European Commission Approves Bristol-Myers Squibb’s Daklinza (daclatasvir) Across Multiple Genotypes for the Treatment of Chronic Hepatitis C Infection Bristol-Myers Squibb / 27 August 2014 Stefan Zeuzem: How I Manage HCV Patients for Whom First-Generation Protease Inhibitors Failed Clinical Care Options (requires registration) / 28 May 2014 MK-5172 + MK-8742 demonstrate good early post-treatment response rates Liz Highleyman / 24 April 2014 A combination of two direct-acting antivirals, MK-5172 and MK-8742, with or without ribavirin, led to early post-treatment sustained response rates above 90% for people with genotype 1 hepatitis C virus (HCV), including ... BMS combination cures 90% of genotype 1b hepatitis C in 24 weeks Caspar Thomson / 17 April 2014 A combination of two direct-acting antivirals developed by Bristol-Myers Squibb (BMS) cured 90% of previously untreated people with genotype 1b hepatitis C infection in 24 weeks, without the need for pegylated interferon ... ← First12345Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive